AWM
GALT icon

AE Wealth Management’s Galectin Therapeutics GALT Stock Holding History

AE Wealth Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-26,841
Closed -$46.4K – 1467
2023
Q4 		$46.4K Hold
26,841
– – ﹤0.01% 1986
2023
Q3 		$51.5K Buy
26,841
+11,300
+73% +$18.6K ﹤0.01% 1879
2023
Q2 		$22.4K Hold
15,541
– – ﹤0.01% 1861
2023
Q1 		$32.6K Hold
15,541
– – ﹤0.01% 1830
2022
Q4 		$17.6K Buy
+15,541
New +$20.7K ﹤0.01% 1789

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AE Wealth Management's GALT Position: Q1 2024 in Review

AE Wealth Management sold out of Galectin Therapeutics (GALT) in Q1 2024, closing a stake of 26,841 shares — an estimated $46.4K sold.

AE Wealth Management first reported a position in GALT in Q4 2022 and held it in 5 quarters. The position peaked at $51.5K in Q3 2023. 59 funds tracked by Wall St. Rank hold GALT as of Q1 2024.

  • AE Wealth Management reported no remaining Galectin Therapeutics position as of Q1 2024 after selling out during the quarter.
  • AE Wealth Management sold 26,841 Galectin Therapeutics shares in Q1 2024, an estimated $46.4K.
  • AE Wealth Management first reported a position in Galectin Therapeutics in Q4 2022 and held it in 5 quarters.
  • AE Wealth Management's Galectin Therapeutics position peaked at $51.5K in Q3 2023.
  • 59 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2024.

Based on AE Wealth Management's 13F filing for Q1 2024, filed 15 May 2024.